Registry-listed formulations

sagopilone · mesh:C530494

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

14 source entries across 8 studies. This list may not include all unresolved or historical entries.

  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302 , ZK219477)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Sagopilone (ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (ZK 219477)Registry intervention

    Molecular identity unconfirmed

    View study and source
  • Sagopilone (BAY86-5302, ZK 219477)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ZK219477Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • ZK-EPORegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
29%(2 trials)
Terminated
2(22%)

Phase Distribution

Phase 1/2
1
11%
Phase 2
8
89%

Phase Distribution

0

Early Stage

9

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1/2Combined phases
1(11.1%)
Phase 2Efficacy & side effects
8(88.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 1/21 (11.1%)
Phase 28 (88.9%)

Trials by Status

terminated222%
completed778%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

NCT00246688
terminatedphase_2

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

NCT00299390
completedphase_2

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

NCT00313248
completedphase_2

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer

NCT00160069
completedphase_2

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

NCT00288249
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00246688Phase 2

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Completed
NCT00299390Phase 2

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

Terminated
NCT00313248Phase 2

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Completed
NCT00160069Phase 2

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer

Completed
NCT00288249Phase 2

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

Completed
NCT00359359Phase 1/2

A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer

Completed
NCT00598507Phase 2

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

Completed
NCT00496379Phase 2

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Terminated
NCT00424060Phase 2

Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma

Completed

All 9 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
9

External References

ChEMBL
CHEMBL2304041

Names & Codes

Research Codes

BAY-86-5302DE-03757EPO-477SH-Y-03757SH-Y03757AZK 219477ZK-EPO